Proteome Sciences PLC
22 December 2003
Proteome Sciences Plc ('the Company')
Directors' Shareholdings
Christopher D J Pearce, a director of the Company, today informed the Company
that on 19 December 2003 he exercised options over 888,889 ordinary shares of 1p
each in the Company ('Ordinary Shares') at a price of 45p each. Following this
transaction, Mr Pearce holds options over a further 2,789,292 Ordinary Shares.
Mr Pearce also notified the Company today that on 19 December 2003 his wife sold
250,000 Ordinary Shares at 220p per share, representing 0.21 per cent. of the
Company's issued share capital. The Ordinary Shares have been sold in order to
satisfy the costs of the option exercise. Following this notification, Mr Pearce
has increased his beneficial interest in the Company by 638,889 Ordinary Shares,
an increase of 14.8 per cent., to 4,962,111 Ordinary Shares, which represents
4.12 per cent. of the issued ordinary share capital of the Company.
James L Malthouse, also a director of the Company, today informed the Company
that on 19 December 2003 he exercised options over 577,778 Ordinary Shares at a
price of 45p each. Following this transaction, Mr Malthouse holds options over a
further 1,346,650 Ordinary Shares.
Mr Malthouse also notified the Company today that on 19 December 2003 he sold
327,778 Ordinary Shares at 220p per share, representing 0.27 per cent. of the
Company's issued share capital. These Ordinary Shares have been sold in part to
satisfy the cost of the option exercise. In addition, Mr Malthouse today
notified the Company that on 19 December 2003 his wife sold 180,937 Ordinary
Shares at 220p per share, representing 0.15 per cent. of the Company's issued
share capital. Following this notification, Mr Malthouse has increased his
beneficial interest in the Company by 69,063 Ordinary Shares, an increase of
38.2 per cent., to 250,000 Ordinary Shares, which represents 0.21 per cent. of
the issued ordinary share capital of the Company.
Application has been made for the 1,466,667 Ordinary Shares to be admitted to
trading on AIM and dealings are expected to commence on 24 November 2003.
22 December 2003
For further information
Christopher Pearce, Proteome Sciences Plc 01932 865 065
James Malthouse, Proteome Sciences Plc
This information is provided by RNS
The company news service from the London Stock Exchange
*A Private Investor is a recipient of the information who meets all of the conditions set out below, the recipient:
Obtains access to the information in a personal capacity;
Is not required to be regulated or supervised by a body concerned with the regulation or supervision of investment or financial services;
Is not currently registered or qualified as a professional securities trader or investment adviser with any national or state exchange, regulatory authority, professional association or recognised professional body;
Does not currently act in any capacity as an investment adviser, whether or not they have at some time been qualified to do so;
Uses the information solely in relation to the management of their personal funds and not as a trader to the public or for the investment of corporate funds;
Does not distribute, republish or otherwise provide any information or derived works to any third party in any manner or use or process information or derived works for any commercial purposes.
Please note, this site uses cookies. Some of the cookies are essential for parts of the site to operate and have already been set. You may delete and block all cookies from this site, but if you do, parts of the site may not work. To find out more about the cookies used on Investegate and how you can manage them, see our Privacy and Cookie Policy
To continue using Investegate, please confirm that you are a private investor as well as agreeing to our Privacy and Cookie Policy & Terms.